Zloto, OfiraWygnanski-Jaffe, TamaraFarzavandi, Sonal K.Gomez-de-Liaño, RosarioSprunger, Derek T.Mezer, Eedy2019-02-152019-02-152018-12Zloto, O., Wygnanski-Jaffe, T., Farzavandi, S. K., Gomez-de-Liaño, R., Sprunger, D. T., & Mezer, E. (2018). Current trends among pediatric ophthalmologists to decrease myopia progression—an international perspective. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256(12), 2457–2466. https://doi.org/10.1007/s00417-018-4078-6https://hdl.handle.net/1805/18402Purpose To explore what the current worldwide preferred practice patterns of pediatric ophthalmologists are to decrease myopia progression among their patients. Methods A questionnaire was sent to all members of supranational and national pediatric ophthalmology and strabismus societies. Results The questionnaire was fully completed by most respondents 90.10% (847 of 940 responses). Fifty-seven percent (457) routinely treat to decrease myopia progression. The most common parameter to initiate treatment was a myopic increase of 1 diopter/year or more (74.8%, 246). Seventy percent (345) prescribed eye drops. Atropine 0.01% was the most popular (63.4%, 277) followed by atropine 1% (10.9%, 48) and atropine 0.5% (8.9%, 39). Eighty-six percent (394) of the respondents advised to spend more time outdoors, to reduce the amount of time viewing screens (60.2%, 277), and cutback the use of smart phones (63.9%, 294). Conclusions Most pediatric ophthalmologists treat to decrease myopia. They employ a wide variety of means to decrease myopia progression. Atropine 0.01% is the most popular and safe modality used similarly to recent reports. However, there is no consensus when treatment should be initiated. Further prospective studies are needed to elucidate the best timing to start treatment and the applicability of recent studies in the Asian population to other ethnic groups. This will improve the ability to update pediatric ophthalmologist with evidenced-based treatment options to counter the myopia epidemic.enIUPUI Open Access PolicymyopiaIPOSCatropineArticle